Drugs / MRx-4DP0004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03851250 | Jul 2019 → Apr 2023 | asthma | 4D pharma plc | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04363372 | Aug → Dec 2020 | COVID-19 | 4D pharma plc | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRx-4DP0004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03851250 ↗ |
| Modality | Other / unclassified | “MRx-4DP0004 is a Live Biotherapeutic Product” NCT03851250 ↗ |
| Route | Oral | “Participants will take two capsules of MRx-4DP0004 twice daily in addition to their existing asthma medication for 12 weeks.” NCT03851250 ↗ |